Table 1 Patient Characteristics
Patient Characteristics | Fosaprepitant group | Control group | p-value |
|---|---|---|---|
N = 40 | N = 39 | ||
n (%) | n (%) | ||
Age | |||
< 2 years | 5 (12.5) | 5 (12.8) | 0.7676 |
2–6 years | 11 (27.5) | 14 (35.9) | 0.5752 |
7–12 years | 11 (27.5) | 8 (20.5) | 0.6432 |
13–17 years | 13 (32.5) | 12 (30.8) | 0.939 |
Sex | |||
Male | 25 (62.5) | 22 (56.4) | 0.7474 |
Female | 15 (37.5) | 17 (43.6) | |
Diagnosis | |||
ALL | 10 (25.0) | 8 (20.5) | 0.8359 |
AML | 0 (0.0) | 1 (2.6) | 0.4937 |
ALL relapse | 2 (5.0) | 2 (5.1) | > 0.9999 |
Astrocytoma | 1 (2.5) | 1 (2.6) | > 0.9999 |
Non-Hodgkin Lymphoma | 4 (10.0) | 5 (12.8) | 0.737 |
Ependymoma | 1 (2.5) | 1 (2.6) | > 0.9999 |
Ewing’s sarcoma | 4 (10.0) | 4 (10.3) | > 0.9999 |
Germinoma | 1 (2.5) | 1 (2.6) | > 0.9999 |
Hepatoblastoma | 3 (7.5) | 2 (5.1) | > 0.9999 |
Hodgkin’s Lymphoma | 2 (5.0) | 1 (2.6) | > 0.9999 |
Medulloblastoma | 2 (5.0) | 1 (2.6) | > 0.9999 |
MDS | 1 (2.5) | 0 (0.0) | > 0.9999 |
Nephroblastoma | 0 (0.0) | 1 (2.6) | 0.4937 |
Neuroblastoma | 3 (7.5) | 3 (7.7) | > 0.9999 |
Osteosarcoma | 1 (2.5) | 2 (5.1) | > 0.9999 |
Renal cell carcinoma | 0 (0.0) | 1 (2.6) | 0.4937 |
Rhabdomyosarcoma | 4 (10.0) | 2 (5.1) | 0.6752 |
T cell lymphoma | 1 (2.5) | 3 (7.7) | 0.3589 |